{"ticker": {"uuid": "274aa9cc-b06b-4575-a1de-c8841d0dd59e", "symbol": "ENGN", "name": "enGene Holdings Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "enGene Therapeutics (NASDAQ: ENGN) posts 54% response in NMIBC study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxONXFWVlFHY0VfcGhab2RodHRlRGFCelJTVk5TT0FBd01ZV1d3Mjhha1E2NUplNmlvQUNadlFwUU4yMnQ2d3NzWUlzdVBxeHdMekVLVlZYb3dxTjlRMmJ0eHZoTEVXUVR6RDJuYnlld1Zkck5LVzNaVU81bjlsdE1UbXhKcTBRWlhUSzhDS1BzQ3RoNUZDQ2FGRE5rMEVYUVM3T2hvdGFMQ1VnMm40TFJqWlk1aw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T20:06:18+00:00", "published_display": "17 Jul 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene appoints Michael Heffernan as board chairman By Investing.com", "summary": "enGene Therapeutics Inc. has appointed Michael Heffernan as the new Chairman of the Board, replacing Dr. Richard Glickman. This leadership change occurs as the company prepares for a pre-Biologics License Application meeting with the FDA in late 2026 for its drug candidate, detal", "url": "https://m.za.investing.com/news/stock-market-news/engene-appoints-michael-heffernan-as-board-chairman-93CH-4372226?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-17T05:09:52", "published_display": "17 Jul 2026 05:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "enGene Therapeutics (Nasdaq: ENGN) names new chair, plans BLA filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOeERDazgxOWhUdWRHVEpKbW1PLTRzWE45QjFTUVBoT3hWeTRJUmhDRERMd2huTk5BbXYtMmJEY2pWSldHV3dCazRXcWMtQ015SG5nalhHWTlKQkhPTFNGa1hJemZDOHcyQlhhVFNBU0dGa1pzd01OZFdMR0lYV3dJR1VKVUhFc0ZVMGhyQ2FxOFdLbmlNVUtGMzJiOEpBZ2ZTZEhHS2dVRmFfMERtVV90dXJiNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:07:12+00:00", "published_display": "16 Jul 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/engene-focuses-board-support-planned-120000712.html", "source_name": "Business Wire", "published_at": "2026-07-16T12:00:00+00:00", "published_display": "16 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Plans Bladder Cancer Drug Filing in 2H 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNMERWS0xDSnJNaUd0YmRnZUc4WjFpMW90RlBuYmxlNTZSUklnREh3RWJnbXV5NHlqNmM2RkNEeU41T3pSM2dlQ2xYZ3k5bmdSNGhZM3RuOG5fSHpMcUhIeWpLNG5zVkozUGNUU1F1OXcwMHBlZ1Zlbm9fa2hCQktPbmMxMDZFa2ZYVXMzT1BqaEdsRU9YZGpHRXdnYnFMMTg1aVJHSjhsLWVKVTJsaVV3Z05QbDZUTldSa3NF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:00:00+00:00", "published_display": "16 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T15:08:06+00:00", "published_display": "04 Jul 2026 15:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGNW) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The TradingKey article provides an earnings forecast for enGene Holdings Inc (ENGNW), highlighting that relevant financial forecasting data for EPS, Revenue, and Net Profit has not yet been disclosed by the company. It notes the current stock price and market cap information but ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engnw/earnings", "source_name": "TradingKey", "published_at": "2026-06-25T22:10:42", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of enGene Holdings Inc (ENGN), including its current stock price, market cap, and a summary of various technical indicators and moving averages. The analysis highlights that based on moving averages and other technical indicators, the cu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engn/technical", "source_name": "TradingKey", "published_at": "2026-06-23T10:10:10", "published_display": "23 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics", "summary": "Ron Cooper has been appointed as the new CEO of enGene Holdings Inc. This news was featured in the Boston Business Journal, which regularly reports on local business developments. The article highlights this key leadership change within enGene Therapeutics.", "url": "https://www.bizjournals.com/boston/c/best-places-to-work/44841/engene-therapeutics.html", "source_name": "The Business Journals", "published_at": "2026-06-20T19:39:15", "published_display": "20 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley cuts Engene stock rating on reduced sales outlook", "summary": "Morgan Stanley downgraded Engene Holdings Inc. to Underweight from Equalweight, reducing its sales estimates for the company's detalimogene treatment due to reduced confidence in its commercial prospects. The firm noted that physicians lack confidence in the LEGEND study supporti", "url": "https://m.uk.investing.com/news/stock-market-news/morgan-stanley-cuts-engene-stock-rating-on-reduced-sales-outlook-93CH-4734602?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T08:40:45", "published_display": "18 Jun 2026 08:40", "sentiment": "negative", "sentiment_pct": 9, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics (ENGN) lifts restructuring and retention cost estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOME9Jc21FaVBwZnNpZ0dlUXRiVnU0UU43MFp3TEFqMGpMaW1OSnNSclhXM3RKbkdIM3FnZ3JEU1VzY0pvWEZOb240aU1WRHpyLVRRX1I1dHF4WERuSWVXYjU5WFdUWHdMRWZHQXZvUjFTdVdSUkVmb0k1QThyanRtR3NTSDZlOEU1MU1tNExXcHRCa2dmXzM0cjZENkNrVkQ4N1dKWXU3QVFPWFZjczk2bmxqZVZxV05Tb1kxbnVR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGNW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of enGene Holdings Inc (ENGNW) focusing on its dividend and stock split history. It indicates that no dividends have been distributed over the past five years and no stock split data is available. The company's stock is currently trading at $0.28", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engnw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:46", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGNW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for enGene Holdings Inc (ENGNW) by business segments and regions. However, it explicitly states that the relevant data has not yet been disclosed by the company, rendering the report unable to provide the reques", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engnw/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:45", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown overview for enGene Holdings Inc (ENGN). It states that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The page also includes current stock p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:10", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGNW) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for enGene Holdings Inc (ENGNW), noting a previous score of 0.00 with no change. It lists several institutional shareholders, including Forbion Capital Partners and BVF Partners L.P., along with their shareholdin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engnw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T18:40:10", "published_display": "17 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for enGene Holdings Inc (ENGN), indicating a \"Buy\" rating based on 13 analysts. It details expected EPS for the previous and next quarters, along with a target price suggesting a significant upside. The report also includes a peer compari", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:10", "published_display": "17 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] enGene Therapeutics Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxONG42ck1qeXBMb2xXU2tQTlpOTDZOQlp1LXoyMmFLcm9YNm9TQXRNckFxUGk1Q1ZubzR5VklHb0dndmxkcWotQVJIMTljdFJ6U2tXM3oxVWJ6anVSMU5DVmtPVjhnZU5UVEY5WTJMMkp1ZGFZUG1kRGV2T2VlYmVqS1FJQlBBaTYxbWNRUXdNNlBJUmJUOVQtdVNYb1pQYlo1b295WHR5ekRyemhCVFVURVJJa29ybXlkYXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lota S. Zoth granted 31,000 options at enGene Therapeutics (ENGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPeU5pTk1kejIzV0liU1lHX2xHclM0TEZCRVVTZ1hUTHJBTUlJbnZHQWQydlNFY0xBd2E1Sm5sRUNYVVVySnZaODRjVkx0V0VqdjFHMG5aYUwwbHZELWM2OG0xNFpWS0Y2aWZMRnFLM3N2cU1MVm9wQ0xJelFuUkpTQkU2OF9wWF9uMjFuellNOUR5ZEp3bnZGNjFGczBaMlFDdktVRXB0Z2ZFTGNGTnNNbFdSV3FDSjc1M3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics (ENGN) grants director 31,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOR2lDZ01kNDhadU5LTkg0ZUVGTE8zemFCVTBxNl9TY081ZVk0dmFPX0Y3aElPQi1hbm8tRWsySXRCbEFlNW9KQ0dzV2twR0Yya3Z0cHdhRi1VaUNPRDRzMWtib3BwYkw1MzRGVlY4aVRMa1VOMHJxUWc4UEdpNTlaWWJIekFzZ2d4RXJIbEJQUlVhb2JhTWdEanRVNjVDbzdXcUE2ZE10dE80V1d5Z0FKdlY3V2V3blRVdEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Engene stock price target on clinical setbacks By Investing.com", "summary": "H.C. Wainwright has reduced its price target for Engene Holdings Inc. (NASDAQ:ENGN) to $4.00 from $6.00, while maintaining a Buy rating, following disappointing clinical updates and a significant decline in its stock price. Several other analyst firms, including Citizens, Raymond", "url": "https://m.za.investing.com/news/stock-market-news/hc-wainwright-cuts-engene-stock-price-target-on-clinical-setbacks-93CH-4330206?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-17T05:40:10", "published_display": "17 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EnGene slashes staff by 50% to preserve cash ahead of regulatory push", "summary": "EnGene Holdings Inc., a genetic medicines company, has reduced its workforce by 50% to conserve cash. This restructuring comes as the company awaits critical data for its bladder-cancer gene therapy drug. The move aims to preserve financial resources during this pivotal period.", "url": "https://www.bizjournals.com/boston/news/2026/06/16/engene-slashes-staff-by-50.html", "source_name": "The Business Journals", "published_at": "2026-06-16T21:10:26", "published_display": "16 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora depression drug fails; EnGene to cut 50% of staff", "summary": "", "url": "https://finance.yahoo.com/m/c4527e70-17f5-3f54-af91-01ba28ff322c/neumora-depression-drug.html", "source_name": "BioPharma Dive", "published_at": "2026-06-16T09:08:00+00:00", "published_display": "16 Jun 2026 09:08", "sentiment": "positive", "sentiment_pct": 55, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics reports Q2 2026 financial results", "summary": "enGene Therapeutics reported Q2 2026 financial results, including $285.2 million in cash, cash equivalents, and marketable securities, and a net loss of $30.2 million. The company plans to submit a Biologics License Application (BLA) with the FDA in the second half of 2026, drive", "url": "https://grafa.com/en/news/united-states/engene-therapeutics-engn-q2-2026-results", "source_name": "grafa.com", "published_at": "2026-06-15T14:39:36", "published_display": "15 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Reports Second Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPYUc1Z0M4cnhaUTFlejVSTzE3aG5wNGdIRGx1bHBfMV9wbjROeHMyaEx6eDZObzMwWU5zazZhUnRvWEJYdTUycWczSzNRZTJyTjJraUY5OHQ2bjhTcHM4MmdwMl9lXzBrY0Z4Z0lRazNmalFqX0VrS2xwWHpPQ0dpU0NpcUQxWGlRWFdobEFsZFU5REdINmRQYVFoUGVZT3lUY3k4R2lnOGlyNDBZZ1MxTUlPLWVGbVpRSG1zcGdVOExHWjNZSXUtSjZnY19MNG5DX0Jzdg?oc=5", "source_name": "Business Wire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics: The Market Overreacted To The Latest Trial Results (NASDAQ:ENGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPVWFabC1mTzkwY1NKOXVuMnN4MElVX204Q19HNUw0VE1ZNllKU1J4WlViMnVITEtDc3dmeUdHVFRIUVR1SEN2eTk4b1hfdDgxVTN2VkFUUDNqLUpaQy1PejIwZ3R5alJlTUJYc3NRd2U3MnVjZ0VFRnJMeDMyM1I0MFU2SWtPai1DUGF4X091WkR3cWVfVExnRlFZaGt3NE0yLUdnSUNETkVVWFlneklUTFpNMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENGN - enGene Therapeutics Inc Stock Price and Quote", "summary": "This article provides a detailed stock price quote and financial data for enGene Therapeutics Inc. (ENGN), a clinical-stage biotechnology company. It includes key financial metrics, insider and institutional ownership, performance indicators, and a comprehensive list of analyst r", "url": "https://finviz.com/stock?t=ENGN", "source_name": "Finviz", "published_at": "2026-06-05T00:40:37", "published_display": "05 Jun 2026 00:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics Inc. Stock Portfolio", "summary": "This page tracks the simulated stock portfolio for enGene Therapeutics Inc., based on their disclosed 13F filings. As of May 25, 2026, the portfolio has one holding, valued at $2.20 billion, and is entirely focused on the Medical Biology sector. The site provides performance metr", "url": "https://intellectia.ai/whales-auto-tracker/institution/engene-therapeutics-inc", "source_name": "Intellectia AI", "published_at": "2026-05-25T20:09:39", "published_display": "25 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics (NasdaqCM:ENGN) Stock Forecast & Analyst Predictions", "summary": "enGene Therapeutics (ENGN) is forecast to grow earnings by 8.8% and revenue by 64.3% annually, although it is expected to remain unprofitable for the next three years with a negative return on equity. The company recently saw a significant price target decrease by analysts follow", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-05-15T18:09:29", "published_display": "15 May 2026 18:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene (ENGN) filing: Cormorant and Bihua Chen report 0 shares", "summary": "Cormorant Asset Management, LP and Bihua Chen have filed an Amendment No. 1 to Schedule 13G/A for enGene Holdings Inc. (ENGN), reporting that they beneficially own 0 shares, which represents 0% of the class. This calculation is based on 66,989,466 shares outstanding as of March 3", "url": "https://www.stocktitan.net/sec-filings/ENGN/schedule-13g-a-en-gene-therapeutics-inc-amended-passive-investment-di-29221d20f696.html", "source_name": "Stock Titan", "published_at": "2026-05-15T17:10:17", "published_display": "15 May 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BML Investment Partners reports 9.95% stake in enGene Holdings (ENGN)", "summary": "BML Investment Partners, L.P. has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 6,669,908 common shares in enGene Holdings Inc. (ENGN), representing 9.95% of the class. The filing indicates shared voting and dispositive power over these shares, with BML Ca", "url": "https://www.stocktitan.net/sec-filings/ENGN/schedule-13g-a-en-gene-therapeutics-inc-amended-passive-investment-di-d8a451f43767.html", "source_name": "Stock Titan", "published_at": "2026-05-14T14:08:45", "published_display": "14 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BML Investment Partners discloses 7.8% stake in enGene (ENGN) on 05/08/2026", "summary": "BML Investment Partners, L.P. has reported a beneficial ownership of 5,225,000 common shares, which represents a 7.8% stake in enGene Holdings Inc. (ENGN) as of May 8, 2026. The SEC filing, a Schedule 13G, indicates shared voting and dispositive power over these shares through BM", "url": "https://www.stocktitan.net/sec-filings/ENGN/schedule-13g-en-gene-therapeutics-inc-passive-investment-disclosure-5-961aa48f77d4.html", "source_name": "Stock Titan", "published_at": "2026-05-14T01:39:07", "published_display": "14 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Privium Fund Management B.V. Makes New Investment in enGene Holdings Inc. $ENGN", "summary": "Privium Fund Management B.V. has reported a new investment in enGene Holdings Inc. (NASDAQ:ENGN), acquiring 352,087 shares valued at approximately $3.18 million in the fourth quarter. This investment constitutes about 0.6% of Privium's portfolio and 0.53% of enGene's outstanding ", "url": "https://www.marketbeat.com/instant-alerts/filing-privium-fund-management-bv-makes-new-investment-in-engene-holdings-inc-engn-2026-05-06/", "source_name": "MarketBeat", "published_at": "2026-05-11T04:09:47", "published_display": "11 May 2026 04:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNdDFzTjhsV2hUcFNyNFZ3aml3WlVnbTRrZUJoazFEcnNoTUNnV1BzbVByNjJ4VWZvN1VqaDM1RTVjMWVDRWx4WnRKR2dwZWRYM0tYV1BUc1g4NzdCUW1Rc0pDRzA4T2lUcGZvdVhiV20xUDFCRGhTOEZ2NElNUDJOMl9FWWQyWmtPVEZqcE9Na3FqNFFVOHBRb2s1eFc3Nk9ONW5WNXNrWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder Cancer Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQckJPbktGUTRBVXBKREx4ZXhWTjdBY3FHaUYxTnVoTk81d1pBMjNKV2lubWlPakFyUUpKV1RfYTBCUld2NzlxSXRtYUp2RzY2c0RpS01wSjRwNVhYZnlQamxrc2lOcG5CaU9vTWlCT0J0aVNRZnVBcmJRYS1wUFl3dEN2c2ZrcFlWVnN0UW5VS1FVSENEWU5qTWlxV0FqVWVqNFkzSTkwTkRGcEN6b0ZuWldpNks3S3Q0YVMtMVRtaC02Q1FUaVdQdkNic2czZUhMN0M1Sg?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed?", "summary": "enGene Therapeutics (ENGN) recently reported interim Phase 2 LEGEND trial data for its bladder cancer drug candidate, detalimogene voraplasmid. While the data showed a 54% complete response rate, the durability of the response was weaker than expected, leading to a significant 76", "url": "https://finance.yahoo.com/sectors/healthcare/articles/engene-therapeutics-engn-down-76-212746271.html", "source_name": "Market source", "published_at": "2026-05-09T18:39:00", "published_display": "09 May 2026 18:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics (ENGN) Is Down 80.6% After Mixed Phase 2 Bladder Cancer Data Update - What's Changed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENGN SEC Filings - enGene Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for enGene Therapeutics (ENGN) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms (Form 4). It highlights how these filings offer insights into the company's c", "url": "https://www.stocktitan.net/sec-filings/ENGN/page-4.html", "source_name": "Stock Titan", "published_at": "2026-05-09T00:40:40", "published_display": "09 May 2026 00:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain", "summary": "", "url": "https://finance.yahoo.com/m/d335da63-fb39-363d-adad-0eb134c82ca5/engene-bladder-cancer-data.html", "source_name": "MarketBeat", "published_at": "2026-05-08T23:05:56+00:00", "published_display": "08 May 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics hit by analyst downgrades as drug data disappoints", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/engene-therapeutics-hit-analyst-downgrades-154144338.html", "source_name": "Investing.com", "published_at": "2026-05-08T15:41:44+00:00", "published_display": "08 May 2026 15:41", "sentiment": "negative", "sentiment_pct": 42, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] enGene Therapeutics Inc. SEC Filing", "summary": "This article reports on an ARS filing by enGene Therapeutics Inc. (ENGN) with the SEC on May 8, 2026, at 04:08 PM. The filing's impact is deemed low, and sentiment neutral. The report also provides an overview of ENGN's stock data, rankings, latest news, and a list of other recen", "url": "https://www.stocktitan.net/sec-filings/ENGN/ars-en-gene-therapeutics-inc-sec-filing-a896822ec486.html", "source_name": "Stock Titan", "published_at": "2026-05-08T15:38:48", "published_display": "08 May 2026 15:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Downgrades EnGene Holdings to Neutral From Buy", "summary": "Guggenheim has downgraded EnGene Holdings (NASDAQ: ENGN) from Buy to Neutral. This change reflects the analyst's updated outlook on the company.", "url": "https://www.moomoo.com/news/post/69658090/guggenheim-downgrades-engene-holdings-to-neutral-from-buy", "source_name": "Moomoo", "published_at": "2026-05-08T13:39:32", "published_display": "08 May 2026 13:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler cuts Engene Holdings stock rating on trial concerns By Investing.com", "summary": "Piper Sandler downgraded Engene Holdings Inc. to Neutral from Overweight and lowered its price target due to concerns about the company's interim clinical data and the competitive profile of its drug, detalimogene. The firm also cited uncertainty regarding the chief medical offic", "url": "https://za.investing.com/news/stock-market-news/piper-sandler-cuts-engene-holdings-stock-rating-on-trial-concerns-93CH-4264187", "source_name": "Investing.com South Africa", "published_at": "2026-05-08T13:09:21", "published_display": "08 May 2026 13:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Downgrades EnGene Holdings to Market Perform From Outperform", "summary": "Oppenheimer has downgraded EnGene Holdings (NASDAQ: ENGN) from an Outperform rating to a Market Perform rating. This change indicates a shift in the analyst's short-term outlook for the company's stock performance.", "url": "https://www.moomoo.com/news/post/69657805/oppenheimer-downgrades-engene-holdings-to-market-perform-from-outperform", "source_name": "Moomoo", "published_at": "2026-05-08T12:38:48", "published_display": "08 May 2026 12:38", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim downgrades Engene stock rating on weaker trial data", "summary": "Guggenheim downgraded Engene Holdings Inc. (NASDAQ:ENGN) to Neutral from Buy after disappointing interim data from its Phase 2 LEGEND study caused the stock to plunge 76%. The firm removed its price target, citing a decline in efficacy compared to a prior analysis, with the drug'", "url": "https://m.uk.investing.com/news/stock-market-news/guggenheim-downgrades-engene-stock-rating-on-weaker-trial-data-93CH-4661687?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-08T08:38:49", "published_display": "08 May 2026 08:38", "sentiment": "negative", "sentiment_pct": 13, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raymond James downgrades Engene Holdings stock rating on trial results By Investing.com", "summary": "Raymond James downgraded Engene Holdings Inc. to Outperform from Strong Buy and reduced its price target significantly following disappointing results from the company's LEGEND study. The complete response rate for patients enrolled after October 2025 dropped to 39% from 63%, cau", "url": "https://m.in.investing.com/news/stock-market-news/raymond-james-downgrades-engene-holdings-stock-rating-on-trial-results-93CH-5390185?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-05-08T08:38:48", "published_display": "08 May 2026 08:38", "sentiment": "negative", "sentiment_pct": 10, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENGN Stock Collapses As Street Slashes Targets After Trial Shock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOU3REejdFWWhrb0d1b1g0azZKSnVsYXZPRjZnSmVBUDVPVUN2bGxrZDRHeEVpY1lzZGdDTFYzcGxTd0xubDU1RnpGV2FkdTVHZmdkYkkycEVQQ21Ya2tKd0hQSllkdk1MZGh0SGdFX3J1dkZ0cUYycnhCWFRrVDU1bEF3?oc=5", "source_name": "StocksToTrade", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENGN Stock Volatile As Traders Track Liquidity And Runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNeHVDelg3SlBjdzV0cTRrd2dBZmdJY3hnZEhBbFBGbjZVejZFU3VfZV9HUEVNWllfbGc1TFo5V1NYRThFWGgwcEhodXptSkluY3JPNHhGb0JJQy1pWVlYYWdKLW1NZmMxYmJCOVBpSG1LaFd1bUplUHpaNEtfb294ZA?oc=5", "source_name": "timothysykes.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "enGene Therapeutics (NASDAQ: ENGN) posts 54% response in NMIBC study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxONXFWVlFHY0VfcGhab2RodHRlRGFCelJTVk5TT0FBd01ZV1d3Mjhha1E2NUplNmlvQUNadlFwUU4yMnQ2d3NzWUlzdVBxeHdMekVLVlZYb3dxTjlRMmJ0eHZoTEVXUVR6RDJuYnlld1Zkck5LVzNaVU81bjlsdE1UbXhKcTBRWlhUSzhDS1BzQ3RoNUZDQ2FGRE5rMEVYUVM3T2hvdGFMQ1VnMm40TFJqWlk1aw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T20:06:18+00:00", "published_display": "17 Jul 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene appoints Michael Heffernan as board chairman By Investing.com", "summary": "enGene Therapeutics Inc. has appointed Michael Heffernan as the new Chairman of the Board, replacing Dr. Richard Glickman. This leadership change occurs as the company prepares for a pre-Biologics License Application meeting with the FDA in late 2026 for its drug candidate, detal", "url": "https://m.za.investing.com/news/stock-market-news/engene-appoints-michael-heffernan-as-board-chairman-93CH-4372226?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-17T05:09:52", "published_display": "17 Jul 2026 05:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics (Nasdaq: ENGN) names new chair, plans BLA filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOeERDazgxOWhUdWRHVEpKbW1PLTRzWE45QjFTUVBoT3hWeTRJUmhDRERMd2huTk5BbXYtMmJEY2pWSldHV3dCazRXcWMtQ015SG5nalhHWTlKQkhPTFNGa1hJemZDOHcyQlhhVFNBU0dGa1pzd01OZFdMR0lYV3dJR1VKVUhFc0ZVMGhyQ2FxOFdLbmlNVUtGMzJiOEpBZ2ZTZEhHS2dVRmFfMERtVV90dXJiNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:07:12+00:00", "published_display": "16 Jul 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/engene-focuses-board-support-planned-120000712.html", "source_name": "Business Wire", "published_at": "2026-07-16T12:00:00+00:00", "published_display": "16 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Plans Bladder Cancer Drug Filing in 2H 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNMERWS0xDSnJNaUd0YmRnZUc4WjFpMW90RlBuYmxlNTZSUklnREh3RWJnbXV5NHlqNmM2RkNEeU41T3pSM2dlQ2xYZ3k5bmdSNGhZM3RuOG5fSHpMcUhIeWpLNG5zVkozUGNUU1F1OXcwMHBlZ1Zlbm9fa2hCQktPbmMxMDZFa2ZYVXMzT1BqaEdsRU9YZGpHRXdnYnFMMTg1aVJHSjhsLWVKVTJsaVV3Z05QbDZUTldSa3NF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:00:00+00:00", "published_display": "16 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T15:08:06+00:00", "published_display": "04 Jul 2026 15:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGNW) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The TradingKey article provides an earnings forecast for enGene Holdings Inc (ENGNW), highlighting that relevant financial forecasting data for EPS, Revenue, and Net Profit has not yet been disclosed by the company. It notes the current stock price and market cap information but ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engnw/earnings", "source_name": "TradingKey", "published_at": "2026-06-25T22:10:42", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of enGene Holdings Inc (ENGN), including its current stock price, market cap, and a summary of various technical indicators and moving averages. The analysis highlights that based on moving averages and other technical indicators, the cu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engn/technical", "source_name": "TradingKey", "published_at": "2026-06-23T10:10:10", "published_display": "23 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics", "summary": "Ron Cooper has been appointed as the new CEO of enGene Holdings Inc. This news was featured in the Boston Business Journal, which regularly reports on local business developments. The article highlights this key leadership change within enGene Therapeutics.", "url": "https://www.bizjournals.com/boston/c/best-places-to-work/44841/engene-therapeutics.html", "source_name": "The Business Journals", "published_at": "2026-06-20T19:39:15", "published_display": "20 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley cuts Engene stock rating on reduced sales outlook", "summary": "Morgan Stanley downgraded Engene Holdings Inc. to Underweight from Equalweight, reducing its sales estimates for the company's detalimogene treatment due to reduced confidence in its commercial prospects. The firm noted that physicians lack confidence in the LEGEND study supporti", "url": "https://m.uk.investing.com/news/stock-market-news/morgan-stanley-cuts-engene-stock-rating-on-reduced-sales-outlook-93CH-4734602?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T08:40:45", "published_display": "18 Jun 2026 08:40", "sentiment": "negative", "sentiment_pct": 9, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics (ENGN) lifts restructuring and retention cost estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOME9Jc21FaVBwZnNpZ0dlUXRiVnU0UU43MFp3TEFqMGpMaW1OSnNSclhXM3RKbkdIM3FnZ3JEU1VzY0pvWEZOb240aU1WRHpyLVRRX1I1dHF4WERuSWVXYjU5WFdUWHdMRWZHQXZvUjFTdVdSUkVmb0k1QThyanRtR3NTSDZlOEU1MU1tNExXcHRCa2dmXzM0cjZENkNrVkQ4N1dKWXU3QVFPWFZjczk2bmxqZVZxV05Tb1kxbnVR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGNW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of enGene Holdings Inc (ENGNW) focusing on its dividend and stock split history. It indicates that no dividends have been distributed over the past five years and no stock split data is available. The company's stock is currently trading at $0.28", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engnw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:46", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGNW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for enGene Holdings Inc (ENGNW) by business segments and regions. However, it explicitly states that the relevant data has not yet been disclosed by the company, rendering the report unable to provide the reques", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engnw/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:45", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown overview for enGene Holdings Inc (ENGN). It states that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The page also includes current stock p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:10", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGNW) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for enGene Holdings Inc (ENGNW), noting a previous score of 0.00 with no change. It lists several institutional shareholders, including Forbion Capital Partners and BVF Partners L.P., along with their shareholdin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engnw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T18:40:10", "published_display": "17 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for enGene Holdings Inc (ENGN), indicating a \"Buy\" rating based on 13 analysts. It details expected EPS for the previous and next quarters, along with a target price suggesting a significant upside. The report also includes a peer compari", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-engn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:10", "published_display": "17 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] enGene Therapeutics Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxONG42ck1qeXBMb2xXU2tQTlpOTDZOQlp1LXoyMmFLcm9YNm9TQXRNckFxUGk1Q1ZubzR5VklHb0dndmxkcWotQVJIMTljdFJ6U2tXM3oxVWJ6anVSMU5DVmtPVjhnZU5UVEY5WTJMMkp1ZGFZUG1kRGV2T2VlYmVqS1FJQlBBaTYxbWNRUXdNNlBJUmJUOVQtdVNYb1pQYlo1b295WHR5ekRyemhCVFVURVJJa29ybXlkYXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lota S. Zoth granted 31,000 options at enGene Therapeutics (ENGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPeU5pTk1kejIzV0liU1lHX2xHclM0TEZCRVVTZ1hUTHJBTUlJbnZHQWQydlNFY0xBd2E1Sm5sRUNYVVVySnZaODRjVkx0V0VqdjFHMG5aYUwwbHZELWM2OG0xNFpWS0Y2aWZMRnFLM3N2cU1MVm9wQ0xJelFuUkpTQkU2OF9wWF9uMjFuellNOUR5ZEp3bnZGNjFGczBaMlFDdktVRXB0Z2ZFTGNGTnNNbFdSV3FDSjc1M3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics (ENGN) grants director 31,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOR2lDZ01kNDhadU5LTkg0ZUVGTE8zemFCVTBxNl9TY081ZVk0dmFPX0Y3aElPQi1hbm8tRWsySXRCbEFlNW9KQ0dzV2twR0Yya3Z0cHdhRi1VaUNPRDRzMWtib3BwYkw1MzRGVlY4aVRMa1VOMHJxUWc4UEdpNTlaWWJIekFzZ2d4RXJIbEJQUlVhb2JhTWdEanRVNjVDbzdXcUE2ZE10dE80V1d5Z0FKdlY3V2V3blRVdEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Engene stock price target on clinical setbacks By Investing.com", "summary": "H.C. Wainwright has reduced its price target for Engene Holdings Inc. (NASDAQ:ENGN) to $4.00 from $6.00, while maintaining a Buy rating, following disappointing clinical updates and a significant decline in its stock price. Several other analyst firms, including Citizens, Raymond", "url": "https://m.za.investing.com/news/stock-market-news/hc-wainwright-cuts-engene-stock-price-target-on-clinical-setbacks-93CH-4330206?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-17T05:40:10", "published_display": "17 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EnGene slashes staff by 50% to preserve cash ahead of regulatory push", "summary": "EnGene Holdings Inc., a genetic medicines company, has reduced its workforce by 50% to conserve cash. This restructuring comes as the company awaits critical data for its bladder-cancer gene therapy drug. The move aims to preserve financial resources during this pivotal period.", "url": "https://www.bizjournals.com/boston/news/2026/06/16/engene-slashes-staff-by-50.html", "source_name": "The Business Journals", "published_at": "2026-06-16T21:10:26", "published_display": "16 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora depression drug fails; EnGene to cut 50% of staff", "summary": "", "url": "https://finance.yahoo.com/m/c4527e70-17f5-3f54-af91-01ba28ff322c/neumora-depression-drug.html", "source_name": "BioPharma Dive", "published_at": "2026-06-16T09:08:00+00:00", "published_display": "16 Jun 2026 09:08", "sentiment": "positive", "sentiment_pct": 55, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics reports Q2 2026 financial results", "summary": "enGene Therapeutics reported Q2 2026 financial results, including $285.2 million in cash, cash equivalents, and marketable securities, and a net loss of $30.2 million. The company plans to submit a Biologics License Application (BLA) with the FDA in the second half of 2026, drive", "url": "https://grafa.com/en/news/united-states/engene-therapeutics-engn-q2-2026-results", "source_name": "grafa.com", "published_at": "2026-06-15T14:39:36", "published_display": "15 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Reports Second Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPYUc1Z0M4cnhaUTFlejVSTzE3aG5wNGdIRGx1bHBfMV9wbjROeHMyaEx6eDZObzMwWU5zazZhUnRvWEJYdTUycWczSzNRZTJyTjJraUY5OHQ2bjhTcHM4MmdwMl9lXzBrY0Z4Z0lRazNmalFqX0VrS2xwWHpPQ0dpU0NpcUQxWGlRWFdobEFsZFU5REdINmRQYVFoUGVZT3lUY3k4R2lnOGlyNDBZZ1MxTUlPLWVGbVpRSG1zcGdVOExHWjNZSXUtSjZnY19MNG5DX0Jzdg?oc=5", "source_name": "Business Wire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics: The Market Overreacted To The Latest Trial Results (NASDAQ:ENGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPVWFabC1mTzkwY1NKOXVuMnN4MElVX204Q19HNUw0VE1ZNllKU1J4WlViMnVITEtDc3dmeUdHVFRIUVR1SEN2eTk4b1hfdDgxVTN2VkFUUDNqLUpaQy1PejIwZ3R5alJlTUJYc3NRd2U3MnVjZ0VFRnJMeDMyM1I0MFU2SWtPai1DUGF4X091WkR3cWVfVExnRlFZaGt3NE0yLUdnSUNETkVVWFlneklUTFpNMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENGN - enGene Therapeutics Inc Stock Price and Quote", "summary": "This article provides a detailed stock price quote and financial data for enGene Therapeutics Inc. (ENGN), a clinical-stage biotechnology company. It includes key financial metrics, insider and institutional ownership, performance indicators, and a comprehensive list of analyst r", "url": "https://finviz.com/stock?t=ENGN", "source_name": "Finviz", "published_at": "2026-06-05T00:40:37", "published_display": "05 Jun 2026 00:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics Inc. Stock Portfolio", "summary": "This page tracks the simulated stock portfolio for enGene Therapeutics Inc., based on their disclosed 13F filings. As of May 25, 2026, the portfolio has one holding, valued at $2.20 billion, and is entirely focused on the Medical Biology sector. The site provides performance metr", "url": "https://intellectia.ai/whales-auto-tracker/institution/engene-therapeutics-inc", "source_name": "Intellectia AI", "published_at": "2026-05-25T20:09:39", "published_display": "25 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics (NasdaqCM:ENGN) Stock Forecast & Analyst Predictions", "summary": "enGene Therapeutics (ENGN) is forecast to grow earnings by 8.8% and revenue by 64.3% annually, although it is expected to remain unprofitable for the next three years with a negative return on equity. The company recently saw a significant price target decrease by analysts follow", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-05-15T18:09:29", "published_display": "15 May 2026 18:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene (ENGN) filing: Cormorant and Bihua Chen report 0 shares", "summary": "Cormorant Asset Management, LP and Bihua Chen have filed an Amendment No. 1 to Schedule 13G/A for enGene Holdings Inc. (ENGN), reporting that they beneficially own 0 shares, which represents 0% of the class. This calculation is based on 66,989,466 shares outstanding as of March 3", "url": "https://www.stocktitan.net/sec-filings/ENGN/schedule-13g-a-en-gene-therapeutics-inc-amended-passive-investment-di-29221d20f696.html", "source_name": "Stock Titan", "published_at": "2026-05-15T17:10:17", "published_display": "15 May 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BML Investment Partners reports 9.95% stake in enGene Holdings (ENGN)", "summary": "BML Investment Partners, L.P. has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 6,669,908 common shares in enGene Holdings Inc. (ENGN), representing 9.95% of the class. The filing indicates shared voting and dispositive power over these shares, with BML Ca", "url": "https://www.stocktitan.net/sec-filings/ENGN/schedule-13g-a-en-gene-therapeutics-inc-amended-passive-investment-di-d8a451f43767.html", "source_name": "Stock Titan", "published_at": "2026-05-14T14:08:45", "published_display": "14 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BML Investment Partners discloses 7.8% stake in enGene (ENGN) on 05/08/2026", "summary": "BML Investment Partners, L.P. has reported a beneficial ownership of 5,225,000 common shares, which represents a 7.8% stake in enGene Holdings Inc. (ENGN) as of May 8, 2026. The SEC filing, a Schedule 13G, indicates shared voting and dispositive power over these shares through BM", "url": "https://www.stocktitan.net/sec-filings/ENGN/schedule-13g-en-gene-therapeutics-inc-passive-investment-disclosure-5-961aa48f77d4.html", "source_name": "Stock Titan", "published_at": "2026-05-14T01:39:07", "published_display": "14 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Privium Fund Management B.V. Makes New Investment in enGene Holdings Inc. $ENGN", "summary": "Privium Fund Management B.V. has reported a new investment in enGene Holdings Inc. (NASDAQ:ENGN), acquiring 352,087 shares valued at approximately $3.18 million in the fourth quarter. This investment constitutes about 0.6% of Privium's portfolio and 0.53% of enGene's outstanding ", "url": "https://www.marketbeat.com/instant-alerts/filing-privium-fund-management-bv-makes-new-investment-in-engene-holdings-inc-engn-2026-05-06/", "source_name": "MarketBeat", "published_at": "2026-05-11T04:09:47", "published_display": "11 May 2026 04:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNdDFzTjhsV2hUcFNyNFZ3aml3WlVnbTRrZUJoazFEcnNoTUNnV1BzbVByNjJ4VWZvN1VqaDM1RTVjMWVDRWx4WnRKR2dwZWRYM0tYV1BUc1g4NzdCUW1Rc0pDRzA4T2lUcGZvdVhiV20xUDFCRGhTOEZ2NElNUDJOMl9FWWQyWmtPVEZqcE9Na3FqNFFVOHBRb2s1eFc3Nk9ONW5WNXNrWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder Cancer Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQckJPbktGUTRBVXBKREx4ZXhWTjdBY3FHaUYxTnVoTk81d1pBMjNKV2lubWlPakFyUUpKV1RfYTBCUld2NzlxSXRtYUp2RzY2c0RpS01wSjRwNVhYZnlQamxrc2lOcG5CaU9vTWlCT0J0aVNRZnVBcmJRYS1wUFl3dEN2c2ZrcFlWVnN0UW5VS1FVSENEWU5qTWlxV0FqVWVqNFkzSTkwTkRGcEN6b0ZuWldpNks3S3Q0YVMtMVRtaC02Q1FUaVdQdkNic2czZUhMN0M1Sg?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed?", "summary": "enGene Therapeutics (ENGN) recently reported interim Phase 2 LEGEND trial data for its bladder cancer drug candidate, detalimogene voraplasmid. While the data showed a 54% complete response rate, the durability of the response was weaker than expected, leading to a significant 76", "url": "https://finance.yahoo.com/sectors/healthcare/articles/engene-therapeutics-engn-down-76-212746271.html", "source_name": "Market source", "published_at": "2026-05-09T18:39:00", "published_display": "09 May 2026 18:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics (ENGN) Is Down 80.6% After Mixed Phase 2 Bladder Cancer Data Update - What's Changed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENGN SEC Filings - enGene Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for enGene Therapeutics (ENGN) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms (Form 4). It highlights how these filings offer insights into the company's c", "url": "https://www.stocktitan.net/sec-filings/ENGN/page-4.html", "source_name": "Stock Titan", "published_at": "2026-05-09T00:40:40", "published_display": "09 May 2026 00:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain", "summary": "", "url": "https://finance.yahoo.com/m/d335da63-fb39-363d-adad-0eb134c82ca5/engene-bladder-cancer-data.html", "source_name": "MarketBeat", "published_at": "2026-05-08T23:05:56+00:00", "published_display": "08 May 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "enGene Therapeutics hit by analyst downgrades as drug data disappoints", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/engene-therapeutics-hit-analyst-downgrades-154144338.html", "source_name": "Investing.com", "published_at": "2026-05-08T15:41:44+00:00", "published_display": "08 May 2026 15:41", "sentiment": "negative", "sentiment_pct": 42, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] enGene Therapeutics Inc. SEC Filing", "summary": "This article reports on an ARS filing by enGene Therapeutics Inc. (ENGN) with the SEC on May 8, 2026, at 04:08 PM. The filing's impact is deemed low, and sentiment neutral. The report also provides an overview of ENGN's stock data, rankings, latest news, and a list of other recen", "url": "https://www.stocktitan.net/sec-filings/ENGN/ars-en-gene-therapeutics-inc-sec-filing-a896822ec486.html", "source_name": "Stock Titan", "published_at": "2026-05-08T15:38:48", "published_display": "08 May 2026 15:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Downgrades EnGene Holdings to Neutral From Buy", "summary": "Guggenheim has downgraded EnGene Holdings (NASDAQ: ENGN) from Buy to Neutral. This change reflects the analyst's updated outlook on the company.", "url": "https://www.moomoo.com/news/post/69658090/guggenheim-downgrades-engene-holdings-to-neutral-from-buy", "source_name": "Moomoo", "published_at": "2026-05-08T13:39:32", "published_display": "08 May 2026 13:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler cuts Engene Holdings stock rating on trial concerns By Investing.com", "summary": "Piper Sandler downgraded Engene Holdings Inc. to Neutral from Overweight and lowered its price target due to concerns about the company's interim clinical data and the competitive profile of its drug, detalimogene. The firm also cited uncertainty regarding the chief medical offic", "url": "https://za.investing.com/news/stock-market-news/piper-sandler-cuts-engene-holdings-stock-rating-on-trial-concerns-93CH-4264187", "source_name": "Investing.com South Africa", "published_at": "2026-05-08T13:09:21", "published_display": "08 May 2026 13:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Downgrades EnGene Holdings to Market Perform From Outperform", "summary": "Oppenheimer has downgraded EnGene Holdings (NASDAQ: ENGN) from an Outperform rating to a Market Perform rating. This change indicates a shift in the analyst's short-term outlook for the company's stock performance.", "url": "https://www.moomoo.com/news/post/69657805/oppenheimer-downgrades-engene-holdings-to-market-perform-from-outperform", "source_name": "Moomoo", "published_at": "2026-05-08T12:38:48", "published_display": "08 May 2026 12:38", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim downgrades Engene stock rating on weaker trial data", "summary": "Guggenheim downgraded Engene Holdings Inc. (NASDAQ:ENGN) to Neutral from Buy after disappointing interim data from its Phase 2 LEGEND study caused the stock to plunge 76%. The firm removed its price target, citing a decline in efficacy compared to a prior analysis, with the drug'", "url": "https://m.uk.investing.com/news/stock-market-news/guggenheim-downgrades-engene-stock-rating-on-weaker-trial-data-93CH-4661687?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-08T08:38:49", "published_display": "08 May 2026 08:38", "sentiment": "negative", "sentiment_pct": 13, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raymond James downgrades Engene Holdings stock rating on trial results By Investing.com", "summary": "Raymond James downgraded Engene Holdings Inc. to Outperform from Strong Buy and reduced its price target significantly following disappointing results from the company's LEGEND study. The complete response rate for patients enrolled after October 2025 dropped to 39% from 63%, cau", "url": "https://m.in.investing.com/news/stock-market-news/raymond-james-downgrades-engene-holdings-stock-rating-on-trial-results-93CH-5390185?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-05-08T08:38:48", "published_display": "08 May 2026 08:38", "sentiment": "negative", "sentiment_pct": 10, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENGN Stock Collapses As Street Slashes Targets After Trial Shock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOU3REejdFWWhrb0d1b1g0azZKSnVsYXZPRjZnSmVBUDVPVUN2bGxrZDRHeEVpY1lzZGdDTFYzcGxTd0xubDU1RnpGV2FkdTVHZmdkYkkycEVQQ21Ya2tKd0hQSllkdk1MZGh0SGdFX3J1dkZ0cUYycnhCWFRrVDU1bEF3?oc=5", "source_name": "StocksToTrade", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENGN Stock Volatile As Traders Track Liquidity And Runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNeHVDelg3SlBjdzV0cTRrd2dBZmdJY3hnZEhBbFBGbjZVejZFU3VfZV9HUEVNWllfbGc1TFo5V1NYRThFWGgwcEhodXptSkluY3JPNHhGb0JJQy1pWVlYYWdKLW1NZmMxYmJCOVBpSG1LaFd1bUplUHpaNEtfb294ZA?oc=5", "source_name": "timothysykes.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 68, "sentiment_summary": {"positive": 12, "negative": 17, "neutral": 39, "score": 46, "total": 68, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 74, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 12.94, "count": 24}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}], "positive_events": 12, "negative_events": 17}, "market_context": {"has_market_context": true, "latest_close": 1.9, "latest_week": "2026-07-10", "one_week_move": 6.7, "four_week_move": 17.3, "twelve_week_move": -76.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.108329, "market_dynamics_buy_signal": false, "relative_strength": -74.74638, "fair_value_gap": -74.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.1583, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.7% over one week, +17.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 8}, {"label": "TradingKey", "count": 7}, {"label": "Investing.com South Africa", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Business Wire", "count": 2}, {"label": "timothysykes.com", "count": 2}, {"label": "The Business Journals", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 61}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 24}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "61", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+6.7% over one week, +17.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "enGene Therapeutics (NASDAQ: ENGN) posts 54% response in NMIBC study"}], "updated_at": "2026-07-18T05:51:44.048525+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}